Send us a text
The hardest part of a clinical trial often happens before it even begins: matching the right patient to the right protocol at the right time. This conversation unpacks why pre-screening has become the chief enrollment bottleneck—and how purpose-built AI, secure platforms, and real partnerships can turn that choke point into a fast lane for access to care.
Together with Hamza Hasan (CEO, Clinical AI; Co-Founder, VisionMed) and Brian Galicia (Global Partner Sales Leader, Microsoft), we map the end-to-end journey from problem to product to scale. Hamza shares how Clinical AI automates pre-screening, document generation, PHI redaction, and multilingual translation to reduce site burden and expand global reach. He also takes us inside VisionMed, a new platform that translates surgical video into structured notes and analytics—laying a practical path from assistive insights today to autonomy in the OR tomorrow.
Brian Galicia opens the hood on Microsoft’s Becoming Frontier framework—employee enablement, customer impact, process transformation, and continuous innovation—while demystifying partner types, co-sell strategy, and the power of unified marketplaces to accelerate discovery and trust.
Security threads through every decision. We talk candidly about why enterprise-grade identity, data protection, and auditability decide which AI survives contact with healthcare reality. We also track a major shift: adoption moving from elite research centers to everyday clinics, as tools integrate into EHRs, respect workflows, and deliver measurable wins like faster time-to-first-patient and fewer screen failures.
If you’re building or buying healthcare AI, you’ll leave with a clear playbook: define the why, prove product truth on real workloads, distribute through marketplaces, align incentives with co-sell, and use agents to automate the grind.
The views and discussions presented in this program may include forward-looking statements regarding the future development and potential applications of artificial intelligence, video analysis technologies, and autonomous surgical systems. These statements reflect current expectations and assumptions that involve risks and uncertainties, and actual results may differ materially. Any products, systems, or technologies referenced that involve medical or surgical applications are subject to regulatory review and clearance by the appropriate regulatory authorities before they may be marketed or used clinically.Regulatory requirements vary by jurisdiction, and compliance obligations may differ across regions.
This content is provided for informational purposes and discussion purposes only and should not be construed as medical advice, product claims, or guarantees of future performance.